focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 220.00
Bid: 218.50
Ask: 219.50
Change: -2.00 (-0.90%)
Spread: 1.00 (0.458%)
Open: 218.50
High: 224.50
Low: 217.00
Prev. Close: 222.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PureTech's Vor Biopharma granted FDA fast track for blood cancer drug

Fri, 10th Sep 2021 10:27

(Alliance News) - PureTech Health PLC on Friday said the US Food & Drug Administration has granted Vor Biopharma fast track designation for its VOR33 drug.

VOR33 was developed by PureTech-founded Vor Biopharma and is an engineered hematopoietic stem cell therapy for acute myeloid leukemia, the most common type of blood cancer in adults. PureTech holds an 8.6% stake in Vor.

"Receiving fast track designation is an important milestone for Vor, which signals the FDA's recognition of the serious and life-threatening medical condition of patients facing acute myeloid leukemia and the potential of VOR33 to address this unmet medical need," said Vor Chief Regulatory & Quality Officer Robert Pietrusko.

The drug aims to improve the standard of transplants for patients who are at high risk of relapse. Boston, Massachusetts-based PureTech commented that VOR33 "has the potential to seamlessly integrate into current transplant settings".

"We will continue to work closely with the FDA to expedite the development of VOR33, which is now actively enrolling in its Phase 1/2a clinical trial for acute myeloid leukemia patients who currently have limited treatment options," added Pietrusko.

Vor plans to report the drug's initial clinical data in the first half of 2022.

Shares in PureTech were up 0.6% at 343.00 pence in London on Friday.

By Josie O'Brien; josieobrien@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Oct 2022 07:10

Puretech Health confirms possible tie-up with Nektar Therapeutics

(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.

Read more
7 Oct 2022 07:10

Puretech Health confirms possible tie-up with Nektar Therapeutics

(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.

Read more
5 Sep 2022 11:40

IN BRIEF: PureTech Health data on fibrosis drug candidate positive

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Posts positive data from a phase 1 trial of its idiopathic pulmonary fibrosis drug candidate LYT-100, or deupirfenidone.

Read more
31 Aug 2022 20:31

TOP NEWS: ConvaTec to join FTSE 100 as abrdn vacates spot

(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, September 19 after completing its quarterly review.

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 11:03

SMALL-CAP WINNERS & LOSERS: Hunting surges as loss narrows, ups payout

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
25 Aug 2022 10:10

IN BRIEF: PureTech Health loss narrows in "exceedingly strong" half

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Pretax loss in the first half 2022 narrows to USD56.0 million from USD94.9 million a year before. This is due to a USD28.4 million gain on the dilution of its equity interest in Gelesis Inc. Revenue grows 21% to USD7.0 million from USD5.8 million. Attributes this to increased grant revenue from the Vedanta CARB-X and BARDA grant, as well as Alivio and PureTech LYT Inc.

Read more
25 Aug 2022 09:25

PureTech first-half mixed as it makes good clinical progress

(Sharecast News) - PureTech Health reported total first-half revenue of $7.03m on Thursday, up from $5.84m year-on-year.

Read more
24 Aug 2022 17:58

IN BRIEF: PureTech Health's Sonde Health signs deal for COPD in India

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says its founded entity, Sonde Health, has signed a multi-year agreement with specialty pharmaceutical company Koye Pharmaceuticals Pvt Ltd. The agreement is to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease in India. This is Sonde's first partnership with a pharmaceutical firm, PureTech adds.

Read more
23 Aug 2022 18:14

TOP NEWS: abrdn indicated to drop out of FTSE 100, F&C to join

(Alliance News) - Almost 18 months after announcing a name change, abrdn PLC's blue-chip status is under threat, according to indicative index changes provided by FTSE Russell on Tuesday.

Read more
22 Aug 2022 09:15

PureTech Health's Akili raises USD163 million via Nasdaq IPO

(Alliance News) - PureTech Health PLC said founded entity Akili Inc will start trading on the Nasdaq Capital Market on Monday, after raising funds which will go towards video-game based treatment for children.

Read more
9 Aug 2022 09:31

PureTech gets USD115 million from sale of Karuna Therapeutics shares

(Alliance News) - PureTech Health PLC on Tuesday announced it received USD115.4 million after selling a portion of its stake in Karuna Therapeutics Inc.

Read more
8 Aug 2022 17:06

LONDON MARKET CLOSE: Strong start to week as US inflation data looms

(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears.

Read more
8 Aug 2022 16:21

IN BRIEF: PureTech shares jump on Karuna Therapeutics trial results

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023.

Read more
1 Aug 2022 21:21

IN BRIEF: PureTech Health's Aliki starts phase three study for SDT-001

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.